EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study

Kyung Ah Han iD, You-Cheol Hwang iD, Shin Je Moon, Ho Chan Cho, Hye Jin Yoo, Sung Hee Choi, Suk Chon iD, Kyoung-Ah Kim, Tae Nyun Kim, Jun Goo Kang, Cheol-Young Park, Jong Chul Won und 3 weitere

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15717 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Kyung Ah Han und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Nowon Eulji Medical Centre, Eulji University, Seoul, South Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucosides, Metformin, Benzhydryl Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: LG Chem, Ltd., LG Chem.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the efficacy and safety of gemigliptin and dapagliflozin dual add‐on therapy (GEMI + DAPA) to metformin in type 2 diabetes (T2D) patients who had inadequate glycaemic control on metformin alone, compared with a single add‐on of either gemigliptin (GEMI) or dapagliflozin (DAPA) to metformin. Materials and Methods In this randomized, double‐blind, double‐dummy, active‐controlled, parallel‐group, phase 3 study, 469 T2D patients treated with a stable dose of metformin for 8 weeks or longer were randomized to receive GEMI + DAPA ( n = 157) and either GEMI ( n = 156) or DAPA ( n = 156). The primary endpoint was change in HbA1c levels from baseline at week 24.

Results

Baseline characteristics including body mass index and T2D duration were similar among groups. At week 24, the least square mean changes in HbA1c from baseline were −1.34% with GEMI + DAPA, −0.90% with GEMI (difference between GEMI + DAPA vs. GEMI −0.44% [95% confidence interval {CI}: −0.58% to −0.31%], P < .01) and −0.78% with DAPA (difference between GEMI + DAPA vs. DAPA −0.56% [95% CI: −0.69% to −0.42%], P < .01). Both upper CIs were less than 0, demonstrating the superiority of GEMI + DAPA for lowering HbA1c. The rates of responders achieving HbA1c less than 7% and less than 6.5% were greater with GEMI + DAPA (84.9%, 56.6%) than with GEMI (55.3%, 32.2%) and DAPA (49.3%, 15.3%). The incidence rate of adverse events was similar across groups, with low incidence rates of hypoglycaemia, urinary tract infection and genital infection.

Conclusions

These results suggest that the addition of GEMI + DAPA to metformin as triple combination therapy was effective, safe and well‐tolerated, especially for T2D patients who experienced poor glycaemic control on metformin alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2GlucosidesMetforminBenzhydryl CompoundsDrug Therapy, CombinationGlycated HemoglobinHypoglycemic AgentsPiperidonesPyrimidinesHumansFemaleMaleMiddle AgedDouble-Blind MethodAgedBlood GlucoseGlycemic ControlAdultTreatment OutcomeHypoglycemiaSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

DPP‐4 inhibitorSGLT‐2 inhibitordapagliflozinmetformintype 2 diabetes

Substanzen

dapagliflozinGlucosidesMetforminBenzhydryl CompoundsLC15-0444Glycated HemoglobinHypoglycemic AgentsPiperidonesPyrimidinesBlood Glucose

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Nowon Eulji Medical Centre, Eulji University, Seoul, South Korea.
  • Division of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, Seoul, South Korea.
  • Division of Endocrinology and Metabolism, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea.
  • Division of Endocrinology and Metabolism, Keimyung University Dongsan Hospital, Daegu, South Korea.
  • Division of Endocrinology and Metabolism, Korea University College of Medicine, Seoul, South Korea.
  • Division of Endocrinology and Metabolism, Seoul National University Bundang Hospital, Seongnam, South Korea.

ORCID-Profile: Kyung Ah Han, You-Cheol Hwang, Suk Chon, Kyong Soo Park

Förderung

  • LG Chem, Ltd.
  • LG Chem

Zitieren

APA

Han, K. A., Hwang, Y. C., Moon, S. J., Cho, H. C., Yoo, H. J., Choi, S. H., Chon, S., Kim, K. A., Kim, T. N., Kang, J. G., Park, C. Y., Won, J. C., Cho, E., Kim, J., & Park, K. S. (2024). Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15717

Vancouver

Han KA, Hwang YC, Moon SJ, Cho HC, Yoo HJ, Choi SH, et al. Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15717

BibTeX
@article{Han2024,
  author = {Han, Kyung Ah and Hwang, You-Cheol and Moon, Shin Je and Cho, Ho Chan and Yoo, Hye Jin and Choi, Sung Hee and Chon, Suk and Kim, Kyoung-Ah and Kim, Tae Nyun and Kang, Jun Goo and Park, Cheol-Young and Won, Jong Chul and Cho, Eunjoo and Kim, Jeongyun and Park, Kyong Soo},
  title = {Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15717}
}
Kostenlos starten →